Safety profile of docetaxel in older patients with metastatic breast cancer.

被引：0
|
作者：
Aapro, MS
Olsen, SR
Alakl, M
Murawsky, M
Hurria, A
机构：
[1] Clin De Genolier, Genolier, Switzerland
[2] Aventis Pharmaceut, Bridgewater, NJ USA
[3] Aventis Pharmaceut, Antony, France
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
532
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [21] Activity and safety of frontline docetaxel and capecitabine combination therapy in patients with metastatic breast cancer(MBC)
    Ceniti, S.
    Liguori, V.
    Turano, S.
    Biamonte, R.
    DeSimone, R.
    Filice, A.
    Manfredi, C.
    Mastroianni, C.
    Rovito, A.
    Viscomi, C.
    Palazzo, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 47 - 47
  • [22] Safety and pharmacokinetics of motesanib diphosphate (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer.
    de Boer, R.
    White, S.
    Mainwaring, P.
    Koczwara, B.
    Ye, Y.
    Sun, Y-N
    Parson, M.
    Braun, A.
    Kotasek, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S272 - S272
  • [23] SAFETY PROFILE OF CHEMOTHERAPY WITH DOCETAXEL AND CISPLATIN FOR RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Shimada, T.
    Kiyota, N.
    Imamura, Y.
    Nishimura, M.
    Funakoshi, Y.
    Tomioka, H.
    Toyoda, M.
    Chayahara, N.
    Mukohara, T.
    Minami, H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [24] Identification of docetaxel in tears from patients with metastatic breast cancer
    Ahmadi, A
    Esmaeli, B
    Rivera, E
    Valero, V
    Adinin, RB
    Hutto, T
    Newman, RA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U13 - U13
  • [25] PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer
    Mohebtash, M.
    Madan, R. A.
    Gulley, J. L.
    Jones, J.
    Pazdur, M.
    Rauckhorst, M.
    Schlom, J.
    Arlen, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Phase I study of liposomal doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    Gasparini, G
    ANNALS OF ONCOLOGY, 2000, 11 : 42 - 42
  • [27] Cancer disparities among patients with advanced metastatic breast cancer.
    Saravia, Diana
    Elson, Leah
    Liang, Hong
    Bilani, Nadeem
    Elimimian, Elizabeth Blessing
    Nahleh, Zeina A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    de Laurentiis, M
    Tortora, G
    Palmieri, G
    de Vita, F
    Colantuoni, G
    de Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 211S - 211S
  • [29] Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer
    Kawamoto, Terufumi
    Shikama, Naoto
    Oshima, Masaki
    Kosugi, Yasuo
    Tsurumaru, Masahiko
    Sasai, Keisuke
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 675 - 679
  • [30] Phase I study of liposomial doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Gasparini, G
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    ANNALS OF ONCOLOGY, 2000, 11 : 28 - 28
12345